OraSure Technologies Inc
OSUR3.300USD
+0.010+0.30%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
243.33MMarket Cap
LossP/E TTM
More Details of OraSure Technologies Inc Company
OraSure Technologies, Inc. provides point-of-care and home diagnostic tests, sample management solutions, and microbiome laboratory and analytical services. The Company's product portfolio is divided into diagnostics products and sample management solutions. Its business consists of the development, manufacture, marketing and sale of diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Its diagnostic products include tests for diseases including COVID-19, HIV and Hepatitis C that are performed on a rapid basis at the point of care, and tests for drugs of abuse that are processed in a laboratory. Its business also includes molecular sample management solutions and services that are used by clinical laboratories, direct-to-consumer laboratories, researchers, pharmaceutical companies, and animal health service and product providers.
Company Info
Ticker SymbolOSUR
Company nameOraSure Technologies Inc
IPO dateNov 17, 1986
CEOMs. Carrie Eglinton Manner
Number of employees501
Security typeOrdinary Share
Fiscal year-endNov 17
Address220 E First St
CityBETHLEHEM
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code18015
Phone15036416115
Websitehttps://www.orasure.com/
Ticker SymbolOSUR
IPO dateNov 17, 1986
CEOMs. Carrie Eglinton Manner
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Kenneth J. (Ken) Mcgrath
Mr. Kenneth J. (Ken) Mcgrath
Chief Financial Officer
Chief Financial Officer
448.46K
-2.72%
Dr. Nancy J. Gagliano, M.D.
Dr. Nancy J. Gagliano, M.D.
Independent Director
Independent Director
158.15K
+72.80%
Mr. John P. Kenny
Mr. John P. Kenny
Independent Director
Independent Director
147.20K
+4.74%
Mr. Lelio Marmora
Mr. Lelio Marmora
Independent Director
Independent Director
130.76K
+93.09%
Hon Dr. David J. Shulkin, M.D.
Hon Dr. David J. Shulkin, M.D.
Independent Director
Independent Director
126.33K
+109.45%
Ms. Anne Messing
Ms. Anne Messing
Chief Commercial Officer
Chief Commercial Officer
--
--
Ms. Mara Glickman Aspinall
Ms. Mara Glickman Aspinall
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Robert W. Mcmahon
Mr. Robert W. Mcmahon
Independent Director
Independent Director
--
--
Mr. Jason Plagman
Mr. Jason Plagman
Vice President - Investor Relations
Vice President - Investor Relations
--
--
Ms. Carrie Eglinton Manner
Ms. Carrie Eglinton Manner
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Kenneth J. (Ken) Mcgrath
Mr. Kenneth J. (Ken) Mcgrath
Chief Financial Officer
Chief Financial Officer
448.46K
-2.72%
Dr. Nancy J. Gagliano, M.D.
Dr. Nancy J. Gagliano, M.D.
Independent Director
Independent Director
158.15K
+72.80%
Mr. John P. Kenny
Mr. John P. Kenny
Independent Director
Independent Director
147.20K
+4.74%
Mr. Lelio Marmora
Mr. Lelio Marmora
Independent Director
Independent Director
130.76K
+93.09%
Hon Dr. David J. Shulkin, M.D.
Hon Dr. David J. Shulkin, M.D.
Independent Director
Independent Director
126.33K
+109.45%
Ms. Anne Messing
Ms. Anne Messing
Chief Commercial Officer
Chief Commercial Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Net product and services revenues - COVID-19
12.90M
43.10%
Net product and services revenues - HIV
9.11M
30.44%
Net product and service revenues -Molecular Products
4.33M
14.48%
Net product and services revenues - HCV
1.42M
4.74%
Other revenues - Other non Product revenues
934.00K
3.12%
Other
1.23M
4.12%
By RegionUSD
Name
Revenue
Proportion
United States
20.34M
67.94%
Africa (Region)
7.19M
24.02%
Europe
1.64M
5.47%
Other Regions
770.00K
2.57%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Net product and services revenues - COVID-19
12.90M
43.10%
Net product and services revenues - HIV
9.11M
30.44%
Net product and service revenues -Molecular Products
4.33M
14.48%
Net product and services revenues - HCV
1.42M
4.74%
Other revenues - Other non Product revenues
934.00K
3.12%
Other
1.23M
4.12%
Shareholding Stats
Updated: Tue, Aug 19
Updated: Tue, Aug 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Private Management Group, Inc.
7.47%
BlackRock Institutional Trust Company, N.A.
7.43%
The Vanguard Group, Inc.
5.70%
Neuberger Berman, LLC
5.68%
Dimensional Fund Advisors, L.P.
5.25%
Other
68.47%
Shareholders
Shareholders
Proportion
Private Management Group, Inc.
7.47%
BlackRock Institutional Trust Company, N.A.
7.43%
The Vanguard Group, Inc.
5.70%
Neuberger Berman, LLC
5.68%
Dimensional Fund Advisors, L.P.
5.25%
Other
68.47%
Shareholder Types
Shareholders
Proportion
Investment Advisor
40.45%
Investment Advisor/Hedge Fund
27.75%
Hedge Fund
21.36%
Individual Investor
5.11%
Research Firm
2.36%
Pension Fund
0.44%
Bank and Trust
0.30%
Venture Capital
0.09%
Insurance Company
0.04%
Other
2.10%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
473
72.08M
98.55%
-16.70M
2025Q1
483
70.23M
93.78%
-12.52M
2024Q4
475
70.81M
94.94%
-10.37M
2024Q3
471
70.30M
94.28%
-10.80M
2024Q2
477
73.05M
98.74%
-8.54M
2024Q1
473
74.45M
97.36%
-5.59M
2023Q4
464
73.29M
99.74%
-5.62M
2023Q3
456
72.50M
98.73%
-4.51M
2023Q2
452
70.73M
96.51%
-2.77M
2023Q1
449
67.74M
89.31%
-3.74M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Private Management Group, Inc.
4.42M
5.91%
+4.42M
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
5.58M
7.45%
+27.48K
+0.50%
Mar 31, 2025
The Vanguard Group, Inc.
4.29M
5.73%
+60.97K
+1.44%
Mar 31, 2025
Neuberger Berman, LLC
4.28M
5.72%
+653.02K
+18.00%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
3.82M
5.11%
-147.56K
-3.72%
Mar 31, 2025
Renaissance Technologies LLC
2.57M
3.44%
-203.30K
-7.33%
Mar 31, 2025
Systematic Financial Management, L.P.
1.65M
2.2%
-26.46K
-1.58%
Mar 31, 2025
Acadian Asset Management LLC
2.76M
3.68%
-144.45K
-4.98%
Mar 31, 2025
American Century Investment Management, Inc.
2.51M
3.35%
+159.29K
+6.79%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Sep 6
Updated: Sat, Sep 6
Name
Proportion
Invesco NASDAQ Future Gen 200 ETF
0.5%
Lattice Hartford Multifactor Small Cap ETF
0.08%
Innovator US Small Cap Managed Floor ETF
0.03%
ProShares UltraPro Russell2000
0.01%
Proshares Ultra Russell 2000
0.01%
ETC 6 Meridian Small Cap Equity ETF
0%
SPDR S&P SmallCap 600 ESG ETF
0%
Inspire Fidelis Multi Factor ETF
0%
ETC 6 Meridian Low Beta Equity Strategy ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
View more
Invesco NASDAQ Future Gen 200 ETF
Proportion0.5%
Lattice Hartford Multifactor Small Cap ETF
Proportion0.08%
Innovator US Small Cap Managed Floor ETF
Proportion0.03%
ProShares UltraPro Russell2000
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
ETC 6 Meridian Small Cap Equity ETF
Proportion0%
SPDR S&P SmallCap 600 ESG ETF
Proportion0%
Inspire Fidelis Multi Factor ETF
Proportion0%
ETC 6 Meridian Low Beta Equity Strategy ETF
Proportion0%
DFA Dimensional US Core Equity Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
